Hepatitis C screening strategies in hemodialysis patients

American Journal of Kidney Diseases

Volumn 38, Issue 1, 2001, Pages 91-97

  Saab, Sammy ^a   Brezina, Maria ^a   Gitnick, Gary ^a   Martin, Paul ^a   Yee Jr, Hal F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Decision analysis; Hemodialysis (HD); Hepatitis C virus (HCV)

Indexed keywords

ALANINE AMINOTRANSFERASE;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMODIALYSIS; HEPATITIS C; HUMAN; IMMUNOBLOTTING; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; SCREENING TEST;

EID: 0034968801     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2001.25199     Document Type: Article

References (45)

1. Serum alanine aminotransferase in hepatitis C screening of patients on hemodialysis
2. National surveillance of dialysis-associated diseases in the United States, 1997
3. Hepatitis C virus infection in medical personnel after needlestick accident
4. Risk of death among chronic dialysis patients infected with hepatitis C virus
5. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease
6. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years
7. Impaired kidney transplant survival in patients with antibodies to hepatitis C virus
8. Histopathological features of hepatitis C in renal transplant candidates
9. Recommendation for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease
10. Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients
11. Hypoaminotransferasemia in patients undergoing long-term hemodialysis: Clinical and biochemical appraisal
12. Chronic hepatitis C infection in patients with end-stage renal disease: Characterization of liver hepatology and viral load in patients awaiting renal transplantation
13. Quantitative assessment of HCV load in chronic hemodialysis patients: A cross-sectional survey
14. Abnormal alanine aminotransferase activity reflects exposure to hepatitis C virus in haemodialysis patients
15. Use and interpretation of HCV diagnostic tests in the clinical setting
16. Serological tests for HCV infection
17. Cost-effectiveness: Definitions and use in the gastroenterology literature
18. A reader's guide to economic analysis in the GI literature
19. Primer on medical decision analysis: Part 5 - Working with Markov processes
20. Primer on medical decision analysis: Part 4 - Analyzing the model and interpreting the results
21. Hepatitis C virus (HCV) infection in haemodialysed patients: HCV-RNA and anti-HCV antibodies (third-generation assays)
22. New insights into hepatitis C virus infection of hemodialysis patients: The implications
23. Hepatitis C virus infections in dialysis units: Prevalence of HCV-RNA and antibodies to HCV
24. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: Failure of commercially available antibody tests to identify a significant number of patients with HCV infection
25. Undiagnosed hepatitis C virus infection in hemodialysis patients: Value of HCV RNA and liver enzyme levels
26. Hepatitis C virus infections in dialysis centers in The Netherlands: A national survey by serological and molecular methods
27. Incidence of seroconversion for hepatitis C virus in chronic haemodialysis patients: A prospective study
28. Prevalence of hepatitis C virus infection in hemodialysis patients: A longitudinal study comparing the results of RNA and antibody assays
29. Influence of hepatitis C virus (HCV) viraemia upon serum aminotransferase activity in chronic dialysis patients
30. Serologic survey for control of hepatitis C in haemodialysis patients: Third-generation assays and analysis of costs
31. Acquisition of hepatitis C virus in hemodialysis patients: A prospective study by branched DNA signal amplification assay
32. Detection of de novo hepatitis C virus infection by polymerase chain reaction in hemodialysis patients
33. New perspectives in the diagnosis of hepatitis C
34. Detection of anti-hepatitis C virus antibodies in patients undergoing dialysis by utilizing a hepatitis C virus 3.0 assay: Correlation with hepatitis C virus RNA
35. Absence of HCV viraemia in anti-HCV-negative haemodialysis patients
36. Serological diagnosis of hepatitis C virus in patients with liver disease in Saudi Arabia. Evaluation of antibody determination by recombinant immunoblot assays in relation to RNA detection by polymerase chain reaction
37. Nomogram for Bayes' theorem
38. A twelve year natural history of hepatitis C virus infection in hemodialyzed patients
39. Seroconversion to hepatitis C virus in dialysis patients: A retrospective and prospective study
40. Reliability of polymerase chain reaction for detection of hepatitis C virus
41. High-throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA
42. Quantification of hepatitis C virus by TaqMan PCR: Comparison with HCV Amplicor Monitor assay
43. A 3-year follow-up of HCV-RNA viraemia in haemodialysis patients
44. Maintenance hemodialysis decreases serum hepatitis C virus (HCV) RNA levels in hemodialysis patients with chronic HCV infection